Pharmacologic treatment of schizophrenia by Kane, John M. & Correll, Christoph U.
he use of medication in the acute and long-term
treatment of schizophrenia remains the cornerstone of dis-
ease management. This paper will attempt to review and
highlight recent developments and current controversies
in the pharmacologic treatment of schizophrenia. In that
context, we will highlight areas where gaps in our knowl-
edge continue to exist, and discuss the types of research
ideally suited to fill these gaps. The treatment of the psy-
chosis risk syndrome, also known as the “prodrome,” and
cognitive dysfunction, an increasingly recognized core fea-
ture of schizophrenia, are dealt with elsewhere in this issue. 
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Despite pharmacologic advances, the treatment of schizophrenia remains a challenge, and suboptimal outcomes are
still all too frequent. Although treatment goals of response, remission, and recovery have been defined more uniformly,
a good “effectiveness” measure mapping onto functional outcomes is still lacking. Moreover, the field has to advance
in transferring measurement-based approaches from research to clinical practice. There is an ongoing debate whether,
and which, first- or second-generation antipsychotics should be used. However, an individualized treatment approach
needs to consider current symptoms, comorbid conditions, past therapeutic response, and adverse effects, as well as
patient choice and expectations. Moreover, acute and long-term goals and effects of medication treatment need to be
balanced. While the acute response to appropriately dosed first-generation antipsychotics may not differ much from
second-generation antipsychotics, advantages of lower rates of extrapyramidal side effects, tardive dyskinesia, and, pos-
sibly, relapse may favor second-generation antipsychotics. However, when considering individual adverse effect profiles,
the differentiation into first- and second-generation antipsychotics as unified classes can not be upheld, and a more dif-
ferentiated view and treatment selection is required. To date, clozapine is the only evidence-based treatment for refrac-
tory patients, and the role of antipsychotic polypharmacy and other augmentation strategies remains unclear, at best.
To improve the treatment outcomes in schizophrenia, research efforts are needed that elucidate biomarkers of the ill-
ness and of treatment response (both therapeutic and adverse effects). Moreover, new treatment options are needed
that affect nondopaminergic targets with relevance for symptom reduction, relapse prevention, enhanced efficacy
for nonresponders, and reduced key adverse effects.  
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First- versus second-generation medications
A major focus of research over the past decade has been
to establish the relative merits of first- and second-gen-
eration antipsychotics. With that, psychiatry has seen the
completion of several large, government-funded trials,
which attempted to apply some of the principles of effec-
tiveness studies to complement data derived from more
traditional efficacy research.
Before providing an overview of these results and dis-
cussing their implications, it will be useful to set the stage
for the shift in prescribing practices and the ensuing cost-
effectiveness questions that emerged in the 1990s.
In the 1970s and 1980s, considerable effort went into
solidifying our knowledge of the indications for and ben-
efits and risks of long-term pharmacotherapy in schizo-
phrenia. A large series of relapse-prevention studies
were conducted demonstrating the ability of continuous
antipsychotic drug administration to significantly reduce
the risks of psychotic relapse and rehospitalization in
comparison with placebo.
1
Neurologic adverse effects
At the same time, increasing concern had developed
regarding the potential of antipsychotic drugs to produce
a variety of neurologic adverse effects, ranging from
acute dystonic reactions to akathisia, parkinsonism, and
tardive dyskinesia. Each one of these conditions were
the subject of epidemiologic, treatment, and outcome
studies which are beyond the scope of this review.
Tardive dyskinesia became a particular concern because
of its potential severity, persistence, and psychosocial as
well as medicolegal consequences. A number of prospec-
tive studies were conducted to determine the incidence
and risk factors for tardive dyskinesia.
2-4 In general, the
risk of new cases of tardive dyskinesia was found to be
5% per year of cumulative drug exposure, with age and
early occurring extrapyramidal side effects being two
important risk factors. In elderly individuals (though
with a different spectrum of diagnoses) receiving
antipsychotic medications for the first time the incidence
was generally fivefold higher.
5
With the development of clozapine, the scientific and
clinical community became convinced that it was possi-
ble to separate the therapeutic effects of antipsychotic
medications from their neurologic extrapyramidal
effects. Although it took many years after these early
observations before clozapine was used on a wide scale
for treatment-refractory patients,
6 the awareness of its
lack of propensity to cause extrapyramidal effects pro-
vided considerable impetus in drug development and
served as a model for “atypicality” (a concept which has
outlived its usefulness, but did serve a useful heuristic
function).
With the introduction of other “second-generation”
antipsychotics (risperidone, olanzapine, quetiapine, etc),
there was considerable focus on differences in the
propensity to cause extrapyramidal syndrome (EPS)
between these agents and first-generation drugs.
7
Overall, the differences were generally significant, but
most often based on comparisons with haloperidol.
Although haloperidol was the market leader at that
point, making such comparisons somewhat logical, con-
cerns have been raised that the choice of that medica-
tion, and its utilization in potentially higher than neces-
sary doses, might have served to accentuate differences
in the risk for neurologic adverse effects. The challenge
of conducting studies, which take into account and ade-
quately control for the relative dose equivalences of spe-
cific medications across a range of illness phases, patient
ages, and outcome domains (ie, therapeutic and adverse
effects), should not be minimized. In fact, one can easily
argue that appropriately validated dose equivalences are
generally lacking, and are usually derived from the
analysis of large data sets from studies which were not
necessarily designed to address these issues.
The largest study conducted comparing three different
doses of haloperidol and three different doses of a sec-
ond-generation medication with placebo
8 provided an
interesting perspective. Even doses of haloperidol as low
as 4 mg were associated with significantly greater EPS
than placebo or the “atypical” medication sertindole. In
addition, a recent meta-analysis
9 examined the effect of
haloperidol dosage on the relative need for antiparkin-
sonian medication in trials comparing second-generation
medications with haloperidol. Overall, the authors found
that the superiority remained whether the dosages of
haloperidol employed were above or below 12 mg/day.
Similarly with tardive dyskinesia, the meta-analyses
which have been conducted
5 support the significantly
reduced risk of tardive dyskinesia with the second-gen-
eration antipsychotics. Overall, the risk appears to be
one fifth of what it had been with conventional medica-
tions. (We will return to this issue in the discussion of
results from the effectiveness studies).
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Metabolic adverse effects
At the same time that clinicians and patients benefited
from a reduction in the risk of neurologic adverse effects,
it became apparent that some of the second-generation
medications had a strong propensity to contribute to an
increase in weight and metabolic adverse effects, such as
insulin resistance and dyslipidemia.
10 It has taken several
years to clarify this risk, the extent to which medications
contributed and the relative risk associated with specific
medications. In addition, it has also become apparent
that drug-naïve patients are likely to show more pro-
nounced effects, even with those medications on the
lower end of the risk spectrum, in comparison with
patients who have already been chronically treated.
11
With accumulating data emphasizing the substantially
shortened life expectancy of patients with schizophre-
nia,
12 the prevention and management of cardiometa-
bolic effects has taken on increasing salience. Given the
challenges confronting patients with chronic psychiatric
conditions in terms of diet, exercise, healthy lifestyle
behaviors, smoking, substance use and abuse, etc, the
proactive medical management of such individuals
remains an enormous unmet need.
13
Relative efficacy
Several literature reviews and meta-analyses have been
published in recent years, which have attempted to
determine the extent to which various drugs and drug
classes differ in their efficacy.
9,14,15
It appears that in the treatment of acute psychosis
among patients with first-episode or recent-onset illness
that there are not significant differences in overall
response rates of psychotic signs and symptoms with dif-
ferent antipsychotic drugs or drug classes.
16-19 In general,
response rates among such patients are quite high.
However, in the maintenance phase of treatment fol-
lowing acute response among first-episode patients, dif-
ferences do begin to emerge favoring second-generation
medications, incuding olanzapine and risperidone,
19-22 as
well as amisulpride, quetiapine, and ziprasidone.
19 In the
treatment of multiepisode patients the picture becomes
more complicated. The enthusiasm with which the sec-
ond-generation drugs were received was fueled by
unmet need, a long period without any new antipsy-
chotics, vigorous marketing, and to some extent “wish-
ful thinking” as clinicians would also like to believe that
they have new and better tools with which to help their
patients.
Over time as the cost of medications escalated, intense
debate ensued about the relative merits of the different
drugs and drug classes. Large “effectiveness” studies
such as CATIE (Clinical Antipsychotic Trials of
Intervention Effectiveness),
17 CUtLASS (Cost Utility of
the Latest Antipsychotic Drugs in Schizophrenia),
3,24 and
EUFEST (European First Episode Schizophrenia
Trial)
19 were intended, to some extent, to clarify this
issue.
The data from these trials must be considered along with
the data from all other trials which have been the sub-
ject of a series of meta-analyses. Single studies, no mat-
ter how large, and meta-analyses, no matter how com-
prehensive, all have their limitations, but it is incumbent
upon us to assimilate, objectively integrate and draw rel-
evant conclusions from the evidence, such as it is.
In comparing first and second-generation antipsychotics
(FGAs and SGAs),
9 Leucht et al found four SGAs
(amisulpride, clozapine, olanzapine, and risperidone) to
be more efficacious than FGAs with effect sizes ranging
from small to medium (0.13 for risperidone and 0.52 for
clozapine). Leucht et al emphasized that the SGAs
which were more efficacious showed these advantages
for both of the specific domains of positive and negative
symptoms, suggesting that their superiority for negative
symptoms does not represent a “core component of
atypicality.” As noted previously, all SGAs had fewer
EPS than haloperidol, even when the latter was used in
doses below 7.5 mg/day.
9
When Leucht et al
9 compared their results to those of
other meta-analyses by Geddes et al, Davis et al, and the
Cochrane Schizophrenia Group, 
25-27 the effect sizes were
generally comparable. All meta-analyses—analyzing
similar data sets—found that amisulpride, clozapine,
olanzapine, and risperidone were significantly more effi-
cacious than FGAs.
When Leucht and colleagues
14 reviewed the head-to-
head comparisons of SGAs they reported a similar pat-
tern. Regarding total PANSS score change, olanzapine
was more efficacious than aripiprazole, quetiapine,
risperidone, and ziprasidone; risperidone was more effi-
cacious than quetiapine and ziprasidone, and amisul-
pride was not statistically different from olanzapine or
risperidone. However, regarding dropouts due to ineffi-
cacy, olanzapine was only superior to quetiapine and
ziprasidone, two SGAs often dosed inappropriately low
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in schizophrenia, and amisulpride was more efficacious
than ziprasidone. Surprisingly, clozapine only proved to
be superior to zotepine and to risperidone in dropouts
due to inefficacy. As the authors suggest, possibly inad-
equate doses of clozapine used in some studies might
have contributed to these findings, which are inconsis-
tent with most of the large individual studies.
In comparing these analyses to the results of CATIE and
CUtLASS, there are some consistencies. In CATIE,
17
olanzapine was superior in dropout rates due to ineffi-
cacy and time on effective treatment (at least when
including the 23% of patients who were rerandomized
to olanzapine), and clozapine (though given openly) was
superior to all other studied SGAs in phase 2.
28 In
CUtLASS,
24 clozapine was superior to other SGAs as
well, but in this study, quality of life, and not all-cause
discontinuation, was the primary outcome measure. This
difference highlights the importance of the choice of the
primary outcome measure, particularly in effectiveness
studies, where the outcome is supposed to address ele-
ments of efficacy, tolerability, patient acceptability, and
functioning. 
Although the meta-analyses tended to find more sup-
port for risperidone’s superiority than CATIE did, the
dose equivalences used in CATIE have been challenged
where the modal dose of risperidone was only 3.9
mg/day. 
However, there were no differences between the indi-
vidually studied SGAs and the FGA comparator per-
phenazine in CATIE,
17 as well as between the class of
clinician’s choice SGAs and FGAs (mainly consisting of
sulpiride, which some consider to be an SGA) in
CUtLASS.
23
The large effectiveness trials have been discussed in great
detail elsewhere. Despite the rigorousness with which we
try to design trials, there are always compromises in both
design and execution that are unavoidable, particularly
when multiple outcome measures are included and mul-
tiple questions are addressed simultaneously.
A particularly important issue which impacts all of the
effectiveness trials was stressed by Kraemer et al.
29
Whether a study is designed to establish superiority of
one treatment or groups of treatments over others or to
establish equivalence is critical. As Kraemer et al sug-
gest, if a study is designed to demonstrate one treat-
ment’s superiority, then statistically nonsignificant results
should not be assumed to be evidence of “equivalence.”
To test this, a true noninferiority design is needed that
generally requires larger samples.
The inevitable conclusions from these data are that
drugs and drug classes are heterogeneous, and that we
should not assume commonalities based on anything
except appropriate comparisons. It is also obvious that
every drug involves its own risks and benefits, and that
clinicians have to evaluate data and make decisions
based on the individual patients’ presentation, history,
sensitivities, preferences, responses, adverse effects, etc
(Table I).
This serves as a segue into the next section of this dis-
cussion, which focuses not so much on which drug to
choose, but how to conceptualize and evaluate response
(both therapeutic and adverse) in order to inform treat-
ment decisions (which may or may not involve changing
medication). It is our firm belief that the real challenges
and opportunities in treating patients with schizophre-
nia lie in how treatments are managed, evaluated, and
potentially altered, rather than which drug one chooses
for an initial trial.
As with all treatment planning, formulating and tracking
treatment goals and outcomes is important (Figure 1).
Illness profile Patient profile Medication profile
History of illness onset and course Vulnerability to adverse effects Efficacy
Tolerance of adverse effects Tolerability (short and long-term)
Insight and attitude toward illness Delivery methods/formulations available
Presenting signs and symptoms Need for monitoring
Preference for treatment approaches Availability/cost
Pharmacokinetics
Past treatment response Comorbid medical conditions
Comorbid psychiatric conditions
Comorbid substance abuse
Social support network
Table I. Considerations in choosing antipsychotic medications.
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Response
An important issue for clinicians is how to decide when
and if a particular treatment is having the desired effect
or is producing adverse effects that are not acceptable.
In psychiatry there are few objective measures compa-
rable to the laboratory tests, physical signs, or imaging
results that can inform treatment decisions in other areas
of medicine. We tend to rely on our subjective impres-
sions of a patient’s (subjective) report and our observa-
tions of changes in their affect, thoughts/speech, and
behavior. We would be better served by using (even
brief) quantitative assessment instruments, but this has
yet to be accepted on a wide scale.
Response to treatment is generally assumed to mean a clin-
ically significant improvement in the “chief complaint” or
the psychopathology associated with the condition. How
do clinicians (and patients) decide when improvement is
“enough,” or whether the treatment should be altered in
some fashion? This requires attention to issues related to
dosage and duration of treatment as well as adherence in
medication-taking, bioavailability, and metabolism.
Although clinical trials often use percentage improve-
ment over baseline to measure treatment “response,” we
are ultimately most interested in where patients end up
in terms of the degree of residual psychopathology. This
in no way diminishes the importance of a major
improvement, but it is likely that the degree of residual
psychopathology will be the critical factor in determin-
ing subsequent treatment decisions.
Remission
From this perspective, the remission criteria
30 are a valu-
able tool. Although some clinicians might assume it
unrealistic to expect remission to occur during a rela-
tively short-term (4- to 6-week) treatment trial, data
from large meta-analyses
31 suggest that a substantial pro-
portion of patients can achieve remission within 4 to 6
weeks.
The proposed remission criteria
30 focused on seven char-
acteristic signs and symptoms associated with the diag-
nosis of schizophrenia and selected the corresponding
items on validated rating scales, such as the Positive and
Negative Syndrome Scale (PANSS),
32 or the Scale for
the Assessment of Positive Symptoms (SAPS)
33 and the
Scale for the Assessment of Negative Symptoms
(SANS),
34 which assessed all of these positive and nega-
tive symptoms. According to the criteria, a patient is in
remission if for example, the eight corresponding
PANSS items are rated as no greater than mild, concur-
rently for at least 6 months. (The criteria have also been
used on a cross-sectional basis as a measure of absolute
treatment response as referenced to previously).
If a patient does not achieve remission, the clinician has
to conduct a thorough evaluation of potential reasons, eg,
diagnostic error, nonadherence, inadequate dosage, inad-
equate blood level, comorbid condition(s), substance
abuse, drug-drug interaction, adverse effects interfering
with clinical response, ineffective drug, etc. After con-
ducting such an evaluation, a decision must be made as
to what action to take based on the results. Assuming that
the only reasonable explanation remains the drug’s lack
of efficacy for that particular patient, then whether to
wait for additional response, add a second drug (of the
same or different class) or carry out a complete switch to
an alternative agent, is the decision that must be made.
Recovery
To capture more than just symptom reduction (response)
or an absolute level of psychopathology (remission), the
concept of recovery has gained more acceptance. This is
due to the fact that functional outcomes are the ultimate
goal of interventions in schizophrenia. In this context,
Liberman and Kopelewicz
35 proposed what has come to
be a widely accepted definition of recovery, including 4
domains with criteria that must all be met concurrently
for at least 2 years. In addition to symptomatic remission
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Figure 1. Treatment stages.
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cational/vocational functioning, the ability to perform
day-to-day living tasks without supervision, and a mini-
mum level of social interactions of at least one social con-
tact per week outside of the family. Unfortunately, even
in a well-staffed first episode program, as few as 13.7%
of patients were able to meet these criteria at least once
during a 5-year follow-up period.
36This indicates that in
addition to pharmacologic treatments and broad psy-
chosocial interventions, targeted psychosocial treatments
will need to be combined in an individualized way to
enhance psychosocial and educational/vocational func-
tioning. Since data from the same group indicated that
stopping medications was the primary reason for symp-
tomatic relapse,
37 strategies to enhance the level of med-
ication adherence are also a critical component for
achieving remission and recovery.
Time course of antipsychotic effect
If all of the above considerations are addressed, one of
the most challenging issues remains whether or not the
patient has had an “adequate” trial. The response to
medications varies considerably between patients. When
we asked experts
38 how long an adequate initial trial
should last, the responses ranged from 2.6 to 5.5 weeks.
Textbooks of psychiatry had generally stated that
response might be delayed for weeks rather than days.
39
Recent meta-analyses have challenged that assumption.
Agid et al
40 evaluated 42 studies including 7450 patients
and found that the greatest proportion of improvement
in psychotic signs and symptoms (even controlling for
placebo response) in short-term trials occurred in the
first week. Leucht et al
41 replicated these results utilizing
individual patient data. In addition, when examining
data available in a subset of patients at 1 year, they
found that most of the drug effect observed at 1 year had
already occurred by week 4. Subsequent post-hoc analy-
ses
42 found significant separation between drug and
placebo effects on positive psychotic symptoms even
after only 24 hours. 
These data have reinvigorated the effort to use early
response/nonresponse as a predictor of subsequent
response.
43,44 Correll et al
45 were the first to attempt to
predict nonresponse at 4 weeks using the change of
symptoms at 1 week in a sensitivity-specificity analysis
in 131 patients receiving uniform treatment with
fluphenazine. When Leucht et al
46 conducted a receiver-
operator analysis to answer this question, a response of
less than 20% improvement on the total Brief
Psychiatric Rating Scale
47 (BPRS) best predicted non-
response at 4 weeks. Chang et al
48 reported similar
results in 123 patients treated with risperidone, and
Leucht et al
49 replicated their earlier findings in 1996
patients from pooled olanzapine clinical trials.
Kinon et al
50 and Ascher-Svanum et al
51 reported on
post-hoc analyses of 1077 patients who had participated
in a series of double-blind trials involving olanzapine
and found that a less than 20% reduction in PANSS
scores at 2 weeks was associated with good predictive
power to identify patients unlikely to respond by 12
weeks. Patients with poor early response were also
found to be more likely to discontinue from the trial and
their cost of care was significantly higher than those with
more robust early response.
51
Kinon et al
52 conducted a prospective study of 630
patients treated with risperidone (2 to 6 mg/day). The
192 patients who completed 2 weeks and experienced a
less than 20% improvement on the PANSS at 2 weeks
were then randomized to either continue on risperidone
or be switched to olanzapine 10 to 20 mg/day for an
additional 10 weeks. This first prospective study of its
kind replicated the results of the retrospective, post hoc
analysis described previously. The initial nonresponders
were unlikely to respond when given up to 10 weeks
additional time on the same medication. The authors
found a very modest gain in switching to olanzapine;
however, specific subgroups of patients might be identi-
fied who benefit more dramatically from a switch, ie,
those who were more severely ill.
Although the thresholds of minimal response and ulti-
mate response are debatable, these results are generally
consistent in suggesting that lack of at least minimal
response after 2 weeks of treatment is a strong indicator
that the current treatment is not likely to bring about
substantial response. (The decision as to what change
measure to use will depend on the goals of the analysis
and such choices should be guided by empirical data
whenever possible). The challenge at this point is to
determine what alternative treatments are likely to have
a greater likelihood of success.
Managing poor or partial responders
There are remarkably few studies which have identified
poor or partial responders and randomly assigned con-
Pharmacological aspects
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senting subjects to alternative strategies while also con-
trolling for the passage of time by including a control
group that stays on the original treatment. This type of
design is needed to determine the efficacy of raising the
dose, adding a second drug, or completely changing the
medication.
Kinon et al
53 reported on 115 newly admitted schizo-
phrenia patients treated for 4 weeks with fluphenazine
20 mg/day. Those who failed to achieve the a priori
defined remission level of positive symptoms (ie, no
more than mild positive symptoms) were randomly
assigned, double-blind, to continue on the same treat-
ment, have the dose quadrupled, or be switched to
haloperidol at an equivalent (20 mg/day) dose and fol-
lowed for an additional 4 weeks. There were no signifi-
cant differences in the outcomes between the three
groups and, overall, only an additional 9% of patients
met remission criteria at 8 weeks. This design needs to
be applied with second-generation medications and ide-
ally should also include polypharmacy and clozapine as
comparators.
There is some suggestion that if a switch from one
antipsychotic to another is implemented that choosing
an agent with a different receptor binding profile would
make the most sense. In a post-hoc analysis of CATIE,
Stroup et al
54 reported that among the 114 subjects who
had been considered unsuccessfully treated with per-
phenazine in Phase I, those who were randomized to
olanzapine or quetiapine did better than those random-
ized to risperidone, which has a more similar pattern of
tight D2 blockade.
Antipsychotic polypharmacy
The notion that switching to a medication with a differ-
ent receptor binding profile might be helpful in poor or
partial responders is also the rationale for antipsychotic
polypharmacy. In addition, the complex receptor bind-
ing profile of clozapine has suggested to some that
attempts to simulate this effect should involve combin-
ing multiple drugs.
There are several reports indicating a high prevalence of
antipsychotic polypharmacy in recent clinical practice.
55
Despite widespread use, there is relatively little evidence
that this strategy is helpful, particularly when clozapine
is not involved.
Correll et al
56 reviewed 19 randomized trials including
1216 subjects. Although the overall results could be
interpreted as suggesting an advantage for combination
therapy in comparison with monotherapy, the factors
which appeared to contribute to this effect limit the con-
clusions that can be drawn for the present context.
Combination therapy was more likely to be efficacious
when administered from the start of treatment rather
than waiting to identify poor or partial responders and
when clozapine was involved. Studies which took place
in China and studies which lasted longer than 10 weeks
were also more likely to be positive. This leaves the
question unresolved as to whether or not adding a sec-
ond antipsychotic is likely to be helpful when a patient
fails to derive an adequate response from an initial trial
of monotherapy with drugs other than clozapine.
Adding a second antipsychotic to mitigate adverse
effects from another medication is a different situation,
and there is some suggestion that, for example, adding
aripiprazole to clozapine can lead to a reduction in
weight and/or lipid abnormalities.
57,58
Clozapine
Since the Kane et al
6 study, clozapine has been consid-
ered the best established treatment for refractory
patients. In addition, clozapine has been shown to be
superior to second-generation antipsychotics even
among patients who were only moderately ill
7 and would
not necessarily have met criteria for true treatment resis-
tance. The superiority of clozapine has been demon-
strated in subsequent individual studies
59,28,24 and meta-
analysis.
60,61,62
However, as mentioned previously, in a recent meta-
analysis by Leucht et al
14 of 28 randomized, head-to-head
comparisons of clozapine with other second-generation
antipsychotic drugs, clozapine did not show consistent
superiority. Nevertheless, many if not most of these stud-
ies used low or very low doses of clozapine or patients
were not truly poor responders.
Other pharmacologic classes 
in augmentation strategies
Numerous other classes of agents have been studied to
determine their ability to augment the effects of antipsy-
chotics in the treatment of patients with schizophrenia,
either in general or in poor or partial responders.
Cochrane reviews of benzodiazipines,
63 lithium,
64 and val-
proate
65 could find no clear evidence of efficacy. A sys-
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66 was also negative.
Lamotrigine has been examined in a Cochrane review
including five studies involving 537 participants.
67 Some
evidence of efficacy was found, but the results were not
considered robust. Tiihonen et al
68 have reported evi-
dence from a post-hoc analysis of patients from five tri-
als involving lamotrigine augmentation of clozapine
which suggested some significant effects, but interpreta-
tion remains difficult because of different designs and
inclusion criteria. Further well-designed studies involv-
ing lamotrigine would be very valuable.
Since available antipsychotics generally have only limited
efficacy for negative symptoms and since negative symp-
toms are closely related to functional outcomes, various
augmentation strategies of antipsychotics have been tested
in this domain. Despite positive results in initial, small scale
trials with N-methyl-D-aspartate (NMDA) receptor ago-
nistic treatments, such as glycine, d-alanine, d-serine, d-
cycloserine, the largest placebo-controlled study of glycine
and d-cycloserine was negative.
69 However, recent trials of
augmentation treatment with glycine transporter inhibitors
have been positive,
70 suggesting that this mechanism may
be more promising. In addition a meta-analysis of 5 small-
scale trials of adjunctive treatment with antidepressants
concluded that these agents may reduce negative symp-
toms in patients with a predominantly negative symptom
profile.
71 However, since depression can mimic negative
symptoms and since these trials had only 16 or less patients
in each treatment arm, more data are needed.
Maintenance treatment
Once the maximum degree of therapeutic response is
achieved after an acute exacerbation, the challenge
becomes maintaining those gains, preventing relapse and
facilitating the ongoing application of appropriate psy-
chosocial and vocational therapies. 
There is little question about the indications for contin-
uing antipsychotic medication on an indefinite basis,
except perhaps in patients who have only experienced
one episode. Even there, however, relapse rates are 82%
after 5 years,
37 and discontinuing medication is associ-
ated with a five times higher risk of relapse than staying
on medication. This does suggest, however, that a small
subgroup of patients might remain free of relapse, but at
present we have no means to identify such individuals
prior to making the decision to stop antipsychotic main-
tenance therapy.
The choice of medication takes on particular importance
when long-term treatment is the focus, as the benefit-
to-risk ratio may change substantially. Some drugs are
associated with greater or lesser degrees of specific long-
term risks, eg, tardive dyskinesia, weight gain, type 2 dia-
betes, dyslipidemia, etc. Risk not only varies by drug, but
of course also from individual to individual. At present,
taking a good history and appropriate ongoing moni-
toring is the best strategy to identify particular risk pro-
files, but it is hoped that in the not-too-distant future
pharmacogenetics might help in informing choice of
optimum treatment(s).
72
With regard to relapse prevention, there is some evidence
that the second-generation antipsychotics are associated
with lower relapse rates than first-generation antipsy-
chotics. Leucht et al
73 conducted a meta-analysis of double-
blind random assignment studies which lasted at least one
year and compared relapse rates between the respective
drugs. The average relapse rate among second-generation
drugs after 1 year was 15% compared with 23% among
first-generation medications, a statistically significant dif-
ference (P<.001) and a relative risk reduction of 35%. We
do not have a definitive explanation for this difference, and
although improved adherence might seem like the most
parsimonious explanation, the data reported from the tri-
als included in the meta-analysis do not support the
assumption that improvements in adherence are a suffi-
cient explanation. It is possible that the differences in
receptor binding profile might explain this effect, but again
clear evidence of any specific receptor effect is lacking.
Adverse effects
The appropriate recognition and treatment of adverse
effects of antipsychotics is relevant in the overall man-
agement of schizophrenia. Adverse effects can interfere
with treatment adherence, functional capacity, subjective
well-being, quality of life, and life expectancy.
14 Like for
efficacy, the measurement and monitoring of side effects
should be part of routine treatment. With regard to
antipsychotics, key adverse effects that should be
assessed regularly include sedation, sleep difficulties, sex-
ual and reproductive system problems, extrapyramidal
side effects and involuntary movements, and weight
change, as well as abnormalities in blood pressure and in
blood lipid and glucose levels.
10,13
Unfortunately, recent data have shown that particularly
the monitoring of potentially problematic metabolic side
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lipids, is quite suboptimal. This is a particular concern, as
people with schizophrenia have been found to have ele-
vated risk factors for cardiovascular morbidity and mor-
tality compared with the general population.
13 It appears
that despite clear warnings and treatment recommenda-
tions,
10 clinician’s monitoring behavior has not increased
in a relevant way, and the monitoring frequency is as low
as in a nonpsychiatric control population treated with
albuterol.
74 Clearly, the field needs to consider reasons for
this and take steps toward comprehensive education and
quality improvement programs.
Switching strategies
As stated above, with few exceptions (eg, in treatment-
refractory patients or to avoid cardiovascular risk factor
accumulation), it may be more important how the currently
available medications are used and sequenced, rather than
which particular medication is used. Due to the fact that a
substantial proportion of patients with schizophrenia
remains symptomatic and functionally impaired, develop
treatment intolerability, or are dissatisfied with their treat-
ment, switching between medications is frequent.
Most clinicians know from experience that changing
medications can be a destabilizing event. In fact, even in
the CATIE phase 1 trial, patients rerandomized in a
double-blind fashion to the same antipsychotic stayed in
the study longer than those who were switched to a dif-
ferent antipsychotic.
75 Unless patients require a switch
for an acute destabilization or life-threatening adverse
event, clinicians need to consider the current psychoso-
cial situation, level of support and symptomatic status of
the primary disorder and of comorbid conditions when
planning for a change in the medication regimen. In
addition, consideration of the pharmacologic profiles of
the pre-switch and the post-switch antipsychotic can also
be helpful to predict the potential emergence of rebound
phenomena that can complicate the switch process. The
potential for rebound and withdrawal phenomena is
greatest when the pre- and post-switch antipsychotics
differ considerably regarding binding affinity for specific
receptors (ie, pharmacodynamic dopaminergic, hista-
minergic, or cholinergic rebound) and/or when they dif-
fer considerably regarding their respective half-life (ie,
pharmacokinetic dopamine rebound when the new
antipsychotic has a much longer half-life and the prior
antipsychotic is discontinued too quickly.)
76
Histaminergic rebound is characterized by a reversal of
the antihistaminergic anxiolytic, calming, sleep-inducing,
and EPS-reducing effects, potentially resulting in
rebound insomnia, anxiety, agitation, EPS, and restless-
ness. Similarly, cholinergic rebound is characterized by
agitation, confusion and EPS, and dopaminergic rebound
can manifest as worsening or newly emerging agitation,
aggression, psychosis, mania, akathisia, or withdrawal
dyskinesia. 
Pharmacodynamic and pharmacokinetic rebound phe-
nomena can be avoided in many cases by implementa-
tion of an overlapping, or “plateau” crosstitration,
77 or
by treating withdrawal/rebound symptoms with time-
limited, targeted use of benzodiazepines, antihistamines,
mirtazapine, anticholinergics, gabapentin, or nonbenzo-
diazepine anxiolytics/sedatives.
Conclusions
Despite pharmacologic advances, the treatment of schiz-
ophrenia remains challenging, and suboptimal outcomes
are still too frequent. Even though treatment goals of
response, remission, and recovery have been defined
more uniformly, the field is lacking a functionally rele-
vant “effectiveness” measure as used in large, pragmatic
trials in cardiology or oncology. Moreover, measure-
ment-based approaches, which are standard in research,
need to be applied more broadly to clinical practice. 
There is an ongoing debate as to whether and which
first- or second-generation antipsychotics should be
used, and in which particular patients. However, an indi-
vidualized treatment strategy needs to consider both
current symptoms, comorbid conditions, past therapeu-
tic and adverse effect response, and patient choice and
expectations. Moreover, acute and long-term goals and
medication effects need to be balanced. While the acute
response to appropriately dosed first-generation antipsy-
chotics may not differ much from second-generation
antipsychotics, advantages of lower rates of extrapyra-
midal side effects, tardive dyskinesia, and, possibly,
relapse may favor second-generation antipsychotics.
However, when considering individual adverse effect
profiles, the differentiation into first- and second-gener-
ation antipsychotics as unified classes cannot be sup-
ported, and a more differentiated view and treatment
selection is required. 
To date, clozapine is the only evidence-based treatment
for refractory patients, and the role of antipsychotic
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remains unclear, at best. To improve the treatment out-
comes in schizophrenia, research efforts are needed that
elucidate biomarkers of the illness and of treatment
response (both therapeutic and adverse effects).
Moreover, new treatment options are needed that affect
nondopaminergic targets with relevance for symptom
reduction in various domains, relapse prevention,
enhanced efficacy for nonresponders, and reduced key
adverse effects. Effective treatments for cognitive dys-
function and negative symptoms and those positively
affecting functional outcomes are sorely needed.
Furthermore, the combined use of pharmacologic and
nonpharmacologic cognitive, behavioral, vocational, and
psychosocial approaches needs to be studied more, and
management strategies for lack of illness insight and
adherence should be developed further. ❏
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Tratamiento farmacológico de la esquizofrenia
A pesar de los progresos farmacológicos, el tratamiento de la esquizofrenia todavía constituye un desa-
fío y los resultados insatisfactorios aun son bastante frecuentes. Aunque se han definido más uniforme-
mente los objetivos terapéuticos de respuesta, remisión y recuperación, aun falta una buena medición de
“efectividad” para delimitar los resultados funcionales. Además, en esta área se tiene que avanzar en la
transferencia de enfoques basados en mediciones que vayan desde la investigación hasta la práctica clínica.
Actualmente existe un debate orientado a si deben o no utilizarse antipsicóticos y cuáles de ellos, sean
de primera o segunda generación. Sin embargo, un enfoque terapéutico individualizado requiere tener en
cuenta los síntomas actuales, las condiciones comórbidas, la respuesta terapéutica previa y los efectos adver-
sos, como también la elección del paciente y sus expectativas. Por otra parte, se deben balancear los obje-
tivos a corto y largo plazo, y los efectos del tratamiento medicamentoso. Aunque la respuesta aguda a dosis
apropiadas de antipsicóticos de primera generación puede que no difiera mucho de los antipsicóticos de
segunda generación, las ventajas de menores frecuencias de efectos secundarios extrapiramidales, disqui-
nesia tardía e incluso recaídas pueden darle ventaja a los antipsicóticos de segunda generación. Sin
embargo, cuando se consideran los perfiles de efectos adversos individuales, puede que no sea suficiente
la diferenciación entre antipsicóticos de primera y segunda generación como grupos de fármacos, y se
requiera de un criterio más diferenciado y de una selección del tratamiento. A la fecha, la clozapina es el
único tratamiento basado en la evidencia para los pacientes refractarios, y aun no está del todo claro el
papel de la polifarmacia antipsicótica y de otras estrategias potenciadoras. Para mejorar los resultados de
los tratamientos en la esquizofrenia, se requiere de esfuerzos que procedan de la investigación y que per-
mitan identificar biomarcadores de la enfermedad y de la respuesta terapéutica (tanto los efectos desea-
bles como los adversos). Además, se necesitan nuevas opciones terapéuticas que no estén dirigidas hacia
los sistemas dopaminérgicos y que influyan en la reducción de los síntomas, la prevención de las recaídas,
el aumento de la eficacia en los no respondedores y la reducción de los principales efectos adversos.   
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Traitement pharmacologique de la schizophrénie
Malgré des avancées pharmacologiques, la schizophrénie reste difficile à traiter et des résultats insatisfai-
sants sont encore trop fréquents. Les cibles thérapeutiques de réponse, rémission et rétablissement ont été
définies de façon plus uniforme mais il manque encore une mesure convenable « d’efficacité » basée sur
les capacités fonctionnelles des patients. De plus, dans ce domaine, il faut avancer en transférant les
approches basées sur les mesures de la recherche à la pratique clinique. Savoir si il faut utiliser des anti-
psychotiques de 1
re ou de 2
e génération et lesquels, fait toujours l’objet de discussions. Un traitement per-
sonnalisé nécessite néanmoins d’envisager les symptômes actuels, la comorbidité, les réponses thérapeu-
tiques antérieures, les effets indésirables ainsi que les choix et les attentes du patient. Il faut en outre mettre
en balance les objectifs et les effets des traitements à court et à long termes. Alors qu’une réponse aiguë
à des antipsychotiques de 1
re génération correctement dosés peut ne pas différer beaucoup d’une réponse
à des antipsychotiques de 2
e génération, les bénéfices d’une fréquence moindre d’effets extrapyramidaux,
de dyskinésie tardive et, peut-être, de rechute, font pencher la balance du côté des antipsychotiques de 2
e
génération. Cependant, si l’on considère les profils individuels des effets secondaires, la distinction dans les
antipsychotiques de 1
re et 2
e générations en tant que classes unifiées, ne tient pas et il est nécessaire d’avoir
une vision plus différenciée et une sélection thérapeutique plus fine. À ce jour, la clozapine est le seul trai-
tement ayant apporté ses preuves pour les patients résistants, le rôle d’une polythérapeutique antipsy-
chotique et des autres stratégies d’augmentation restant au mieux obscur. L’amélioration des résultats
du traitement dans la schizophrénie passe par des efforts de la recherche pour trouver des biomarqueurs
de la maladie et de la réponse au traitement (effets thérapeutiques et effets indésirables). Ajoutons que
de nouveaux choix de traitement sont nécessaires en ce qui concerne des cibles non dopaminergiques en
tenant compte de la diminution des symptômes, de la prévention des rechutes, de l’augmentation de l’ef-
ficacité chez les non-répondeurs et de la diminution des effets indésirables majeurs.
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